Drugs / ALG-000184
ALG-000184
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07342881 | Feb → Jun 2026 overdue | chronic hepatitis B virus infection | Aligos Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07342868 | Jan → Apr 2026 overdue | chronic hepatitis B virus infection | Aligos Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06672900 | Jan → Jul 2025 overdue | — | Aligos Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04536337 | Oct 2020 → Jun 2025 | chronic hepatitis B virus infection | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06963710 | Jul 2025 → Mar 2027 expected | chronic hepatitis B virus infection | Aligos Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 36
| Date | Issuer | Release |
|---|---|---|
| 2026-05-27 | Xiamen Amoytop Biotech Co., Ltd. | Regulatory 百年儿科匠心 助力健康中国建设 | 院企合作，共同开启儿童罕见病防治新篇章 amoytop.com ↗
5月26日，国 家 药 品 监 督 管 理 局 药 品 审 评 中 心（CDE）官 网 显 示，特 宝 生 物 引 进 的 慢 性 乙 肝 新 药ALG-000184片（Pevifoscorvir sodium）拟 纳 入 突 破 性 疗 法，用 于 治 疗 初 治 或 目 前 未 治 疗 的 慢 性 乙 型 肝 炎 病 毒 感 染 者 以 达 到 长 期 病 毒 学 抑 制 的 目 标. |
| 2026-05-27 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 aligos.com ↗
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir |
| 2026-05-13 | Aligos Therapeutics | Results Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 aligos.com ↗
Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy |
| 2026-05-07 | Aligos Therapeutics | Results Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results aligos.com ↗
In addition, we completed the first interim analysis for the B-SUPREME HBeAg- cohort with a positive outcome reflecting that the study will continue, the futility criteria were not met, and study drugs were well tolerated. |
| 2026-04-14 | Aligos Therapeutics | Results Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation aligos.com ↗ |
| 2026-02-23 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) aligos.com ↗
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. |
| 2025-12-11 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at HEP-DART 2025 aligos.com ↗
The complete 96-week and post-treatment follow up data from the Phase 1 monotherapy (NCT04536337) cohorts in subjects with chronic HBV infection show the continued potential of pevifoscorvir sodium to become a first-line therapy for chronic suppression. |
| 2025-11-10 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 aligos.com ↗
In the HBeAg- subjects, 8 of 9 subjects switched to NA monotherapy, and all 8 (100%) subjects maintained HBV DNA < LLOQ (10 IU/mL, TD or TND) throughout the NA only 8-week follow-up period. |
| 2025-10-07 | Aligos Therapeutics | Results Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 aligos.com ↗
Oral Once -Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates potent suppression of HBV DNA in Treatment-Naive or Currently-not-treated Subjects with Chronic HBV |
| 2025-09-03 | Aligos Therapeutics | Results Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting aligos.com ↗
With the Phase 2 B-Supreme study progressing nicely, we are pleased to present, for the first time, the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting. |
| 2025-05-08 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 aligos.com ↗
All subjects in both the HBeAg+ and HBeAg- cohorts have achieved HBV DNA viral suppression < LLOQ (10 IU/mL) and continue to demonstrate sustained log10 reductions in viral antigens such as HBcrAg. |
| 2025-04-23 | Aligos Therapeutics | Results Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 aligos.com ↗
Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection |
| 2025-03-26 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at APASL 2025 aligos.com ↗
Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated HBV DNA suppression (<LLOQ <10 IU/mL) in 9/9 (100%) HBeAg+ subjects. |
| 2024-11-19 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 aligos.com ↗
Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (<LLOQ <10 IU/mL) in 7/7 (100%) HBeAg-positive CHB subjects. |
| 2024-10-22 | Aligos Therapeutics | Regulatory Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 aligos.com ↗ |
| 2024-10-15 | Aligos Therapeutics | Results Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 aligos.com ↗
Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection |
| 2024-06-05 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 aligos.com ↗
Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (<LLOQ <10 IU/mL) in 9/10 (90%) HBeAg-positive CHB subjects with no viral breakthrough. |
| 2024-05-22 | Aligos Therapeutics | Results Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 aligos.com ↗
Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAb trends |
| 2024-03-27 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies aligos.com ↗
The three oral presentations provide interim data from Parts 3 and 4 of Aligos’ ALG-000184 Phase 1 extended dosing study showing consistent, potent antiviral activity |
| 2023-12-07 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) aligos.com ↗
Oral dosing with 300 mg of ALG-000184 ± entecavir (ETV) for up to 48 weeks in untreated HBeAg positive chronic hepatitis B patients demonstrated a favorable safety profile and greater suppression of HBV DNA and RNA versus ETV alone |
| 2023-11-10 | Aligos Therapeutics | Results Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg) aligos.com ↗ |
| 2023-06-21 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗
Specifically, a majority of HBeAg positive subjects dosed with 300 mg ALG-000184 + entecavir (ETV) for up to 36 weeks demonstrated time-dependent HBsAg reductions, with a maximum reduction of 2.0 log10 IU/mL observed in week 36. |
| 2023-06-07 | Aligos Therapeutics | Results Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗
Dosing with ALG-000184 plus ETV resulted in dose-dependent, clinically relevant declines in HBsAg, suggesting a potential role of ALG-000184 in combination regimens for functional cure. |
| 2023-04-11 | Aligos Therapeutics | Results Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023 aligos.com ↗
Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B |
| 2023-02-16 | Aligos Therapeutics | Results Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver aligos.com ↗ |
| 2023-02-14 | Aligos Therapeutics | Results Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver aligos.com ↗
In addition, we are pleased to show exciting data for our CAM-E, ALG-000184, demonstrating notable reductions in HBsAg levels in patients with HBeAg-positive CHB. |
| 2022-11-04 | Aligos Therapeutics | Results Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022 aligos.com ↗
ALG-000184 reduced hepatitis B surface antigen (HBsAg) levels in a subset of HBeAg-positive subjects |
| 2022-10-21 | Aligos Therapeutics | Results Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022 aligos.com ↗
We are excited to provide an update at the conference on our clinical-stage drug candidates, particularly our Class 2 capsid assembly modulator (CAM) for CHB, ALG-000184, which continues to show best-in-class declines in a variety of viral markers. |
| 2022-06-22 | Aligos Therapeutics | Results Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022 aligos.com ↗
To date, our CAM program has shown dramatic reductions in viral DNA and RNA in CHB patients following 28 days of dosing in several CHB patient cohorts and dosing in additional cohorts is ongoing. |
| 2021-12-07 | Aligos Therapeutics | Results Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021 aligos.com ↗
New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients |
| 2021-11-12 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 aligos.com ↗
Aligos’ capsid assembly modulator (CAM) candidate, ALG-000184, achieved rapid, substantial reductions in hepatitis B virus DNA and RNA in CHB patients after 28 daily doses |
| 2021-06-10 | Aligos Therapeutics | Results Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects at HBV-TAG Conference aligos.com ↗
In addition to being well tolerated, 100 mg of ALG-000184 given over 14 days resulted in a mean reduction in hepatitis B virus (HBV) DNA of 2.9 log10 IU/mL. |
| 2021-02-03 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver aligos.com ↗
ALG-020572, a next generation hepatitis B virus (HBV) antisense oligonucleotide (ASO) with bridged nucleic acid chemistry, has a significantly improved preclinical profile |
| 2020-09-28 | Aligos Therapeutics | Regulatory Aligos Therapeutics Receives Clinical Trial Application Approval for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184 aligos.com ↗
ALG-000184 is the second of Aligos’ chronic hepatitis B (CHB) drug candidates cleared to begin clinical trials. |
| 2020-08-27 | Aligos Therapeutics | Results Aligos Therapeutics to Present Nonclinical Data for All Components of Chronic Hepatitis B Combination Therapy at EASL Digital International Liver Congress 2020 aligos.com ↗
ALG-000184, a prodrug of ALG-001075, showed improved pharmacokinetic properties, including improved aqueous solubility, stability and oral absorption across species with efficient conversion to ALG-001075 in vivo. |
| 2020-08-24 | Aligos Therapeutics | Regulatory Aligos Therapeutics Submits Clinical Trial Application for Chronic Hepatitis B Capsid Assembly Modulator Candidate ALG-000184 aligos.com ↗ |
All press releases naming this drug 49 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-000184 | “Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium” NCT07342868 ↗ |
| Known as | Pevifoscorvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07342868 ↗ |
| Known as | pevifoscorvir sodium | “Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium” NCT07342868 ↗2“ALG-000184 (pevifoscorvir sodium) is a prodrug of the class-E” PMID 41554267 ↗ Jan 2026 “Pevifoscorvir Sodium (ALG-000184)” NCT07342881 ↗ |
| Action | Inhibit | “ALG-000184 is a prodrug that is converted to ALG-001075, a Class E CAM that inhibits HBV replication through two mechanisms:” NCT04536337 ↗ |
| Modality | Other / unclassified | “ALG-000184 is a prodrug that is converted to ALG-001075, a Class E CAM” NCT04536337 ↗ |
| Route | Oral | “Eligible patients were randomly assigned (4:1) to receive 28 days of oral ALG-000184 (10 mg, 50 mg, 100 mg, or 300 mg) or matching placebo once per day.” PMID 41554267 ↗ Jan 2026 |